GSK Defends Against US FDA Doubts About Jemperli Confirmatory Trial Feasibility
Executive Summary
ODAC meeting on dostarlimab rectal cancer development program highlights issues at top of mind for the agency, including whether a proposed randomized trial in a different setting can be completed, timeline for development of evidence to verify clinical benefit, and challenges with using external controls for single-arm studies.